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genotypes ‘homozygous wild-type’ (TT), ‘heterozygous’ (CT) 
and ‘homozygous variant’ (CC).  Results: About 2.88% of IBD 
patients were identified with CC, 26.8% with CT and 70.4% 
with TT genotype. The CC-genotype was associated with the 
existence of gallstones in CD and pancolitis in UC patients. 
The presence of the C-allele (i.e. either CC or CT genotype) 
was associated with the onset of uveitis, but protected from 
aphthous oral ulcers in CD patients. UC patients carrying a 
C-allele were diagnosed at an older age but required intesti-
nal surgery more often. The presence of the C-allele was as-
sociated with a successful treatment with anti-TNF antibod-
ies in both CD and UC patients.  Conclusion: IBD patients car-
rying the C-allele of PTPN2 SNP rs1893217 are at greater risk 
for developing a severe disease course but are more likely to 
respond to treatment with anti-TNF antibodies. These find-
ings demonstrate a clinical relevance of this PTPN2 risk vari-
ant in IBD patients.  © 2016 S. Karger AG, Basel 
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 Abstract 
 Background/Aims: The single nucleotide polymorphism 
(SNP) rs1893217 within the gene locus encoding protein ty-
rosine phosphatase non-receptor type 2 (PTPN2) results in a 
dysfunctional PTPN2 protein is associated with Crohn’s dis-
ease (CD) and exists in perfect linkage disequilibrium with 
the CD- and ulcerative colitis (UC)-associated PTPN2 SNP 
rs2542151. We investigated associations of PTPN2 SNP 
rs1893217 and clinical characteristics of inflammatory bowel 
disease (IBD) patients.  Methods: One thousand seventy 
three patients with CD and 734 patients with UC from the 
Swiss IBD Cohort Study (SIBDCS) were included. Epidemio-
logic, disease and treatment characteristics were analysed 
for an association with the presence of one of the rs1893217 
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 Introduction 
 Recent genome-wide association studies identified 
>190 risk gene loci being associated with inflammatory 
bowel disease (IBD) to date  [1, 2] . One of those risk loci 
lies within the gene locus encoding for protein tyrosine 
phosphatase non-receptor type 2 (PTPN2). Originally, the 
PTPN2 single nucleotide polymorphism (SNP) rs2542151 
had been associated with both, Crohn’s disease (CD) and 
ulcerative colitis (UC)  [3–5] . This polymorphism is in 
perfect linkage disequilibrium with a further SNP within 
the PTPN2 gene locus, namely 1893217  [6] . Using blood 
samples from the patient collective of the Swiss IBD Co-
hort Study (SIBDCS), we have previously validated this 
correlation in CD patients and demonstrated that the 
PTPN2 SNP rs1893217 is associated with the occurrence 
of CD  [4] . This is of particular importance, since we have 
shown that the presence of the SNP rs1893217 causes dys-
function of the PTPN2 protein product  [4] .
 On a functional level, PTPN2 plays a critical role for 
immune and epithelial cell function, and loss of PTPN2 
activity results in a breakdown of the intestinal epithelial 
barrier, aberrant cytokine secretion and dysfunctional 
autophagy in vitro  [4, 7–10] . PTPN2 knock-out mice fea-
ture severe alterations in erythropoiesis, thrombopoiesis 
as well as B- and T-cell function and finally die within a 
few weeks after birth due to progressive systemic inflam-
mation  [11, 12] . Using mice featuring a knock-out of 
PTPN2 in T-cells, it has been demonstrated that PTPN2 
is a critical negative regulator of T-cell receptor signaling, 
and T-cell specific loss of PTPN2 promotes autoimmune 
and inflammatory conditions  [13, 14] .
 We have recently shown that the loss of PTPN2 in 
CD4-positive cells results in severe colitis and the onset 
of systemic inflammation, for example, in the liver, kid-
neys and the skin, in the dextran sodium sulfate colitis as 
well as in the transfer colitis mouse model. Further, these 
mice exhibit elevated levels of dsDNA antibodies, anti-
nuclear antibodies and anti-mitochondrial antibodies 
underlining the systemic inflammatory effect of PTPN2 
dysfunction. Of particular interest, we found that PTPN2 
dysfunction results in a dysregulation of CD4-positive T-
cell subsets by enhancing levels of Th1 and Th17, but re-
ducing levels of regulatory T-cells. These observations 
could be fully confirmed using serum samples from 
 SIBDCS patients carrying the CD-associated PTPN2 risk 
allele. Additionally, mice featuring a loss of PTPN2 in 
CD4-positive T-cells featured similar alterations in the 
composition of the intestinal microbiota than those that 
can be observed in CD patients  [15] .
 These observations strongly suggest investigating 
whether the presence of the CD-associated gene variant 
rs1893217 is associated with certain clinical characteris-
tics in IBD patients. To date, data about the clinical rele-
vance of the presence of the IBD-associated risk variants 
are rare and a better understanding about these associa-
tions might critically contribute to a better understanding 
of the complex pathophysiology of IBD as well as to a bet-
ter characterization and ultimately prediction of the clin-
ical course of IBD patients, which thus might finally have 
an impact on treatment decisions and algorithms.
 Using the unique patient collective of the SIBDCS, we 
aimed at investigating, whether the presence of the PTPN2 
risk variant, rs1893217 is associated with distinctive dis-
ease characteristics in IBD patients from the  SIBDCS.
 Material and Methods 
 Study Design 
 Patient data were entirely obtained from the register of the na-
tionwide SIBDCS, in which patients with IBD from all regions of 
Switzerland have prospectively been included since 2006  [16] . The 
cohort study is supported by the Swiss National Science Founda-
tion and approved by the local ethical committees (IRB approval 
number: EK-1316, approved on February 5, 2007 by the Cantonal 
Ethics Committee of the Canton Zürich, Switzerland). The cohort 
goals and methodology are described elsewhere  [16] .
 We included 1,843 IBD patients who were enrolled in the study 
at the time of data acquisition and had been previously genotyped 
for the CD-associated risk variant rs1893217 within the PTPN2 gene 
locus. Genotyping had been performed as a large approach by which 
the patient collective of the SIBDC was genotyped for the presence 
of genetic variations in all of the currently known IBD risk loci. One 
thousand seventy three patients had CD, 734 had UC and 46 had 
indeterminate colitis (IC). Due to low patient numbers, IC patients 
have been excluded from the analysis, unless otherwise stated. Of 
note, the rs1893217 polymorphism is in perfect linkage disequilib-
rium with PTPN2 polymorphism rs2542151, which has been previ-
ously associated with both, CD and UC  [3, 4] . The PTPN2 polymor-
phism rs1893217 occurs in 3 possible genotypes: homozygous wild-
type (TT), heterozygous (CT), and homozygous variant (CC). The 
goal of this study was to analyse whether the presence of the CT- or 
CC-form is associated with clinical characteristics of IBD patients.
 Clinical phenotypes were classified with regard to disease loca-
tion, which was stratified into 1 of 4 groups according to the Mon-
treal classification and analysed separately for initial location and 
current location: ileal disease with or without disease limitation to 
the cecum (L1), a disease limited to the colon (L2), an ileal disease 
with disease of the colon beyond the cecum (L3), or disease of the 
upper gastrointestinal tract (L4). Patients with fistulae were classi-
fied into 4 groups: perianal fistula, other type fistula (non-perianal 
fistula), multiple fistulae and any type fistula. The presence of any 
intestinal stenosis was included in the analysis as positive for steno-
sis. UC was classified according to the Montreal classification  [17] 
into proctitis (L1), left-sided colitis (L2), pancolitis (L3) or ‘location 
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unknown’. We also included the history of intestinal surgery. Gen-
der, age at diagnosis, smoking history, and the presence of extraint-
estinal manifestations (EIM) were taken into account. We further 
obtained data about current and prior treatment with 5-amino-
salicylate, antibiotics, steroids, immunosuppressants (namely 
azathioprine/6-mercaptopurine), calcineurin inhibitors (tacrolim-
us, cyclosporine), and anti-TNF drugs (infliximab, adalimumab, 
and certolizumab) at enrollment or according to the term ‘ever treat-
ed with’. Anti-TNF non-response was defined as one of the follow-
ing: (1) breakthrough/loss of response, (2) primary non response 
(never effective), (3) therapy stop due to side effects/intolerance.
 The ethnic background of 1,328 of the 1,843 studied patients is 
known and is as follows: European: 1,234 (80.65% of 1,530), 
 African: 19 (1.24%), Asian: 18 (1.18%), Hispanic: 27 (1.76%), 
 Jewish: 22 (1.44%), other: 8 (0.52%). The remaining patients did 
not give us information about their ethnic background.
 Statistical Analysis 
 Clinical data were retrieved from the data center of the SIBDCS 
at the University of Lausanne. These data and additional data ob-
tained from a review of the patients’ files were entered into a data-
base (access 2000; Microsoft Switzerland Ltd., Liab., Co., Wal-
lisellen, Switzerland). The Statistical Package for the Social Sci-
ences (version 21; SPSS, Chicago, Ill., USA) was used for the 
statistical analysis.
 Crude differences about the association of the PTPN2 variant 
in relation to fistulae, stenosis, smoking status, disease location, 
age at diagnosis, medications and history of intestinal resection 
surgery were assessed using the Pearson’s chi-square test or the 
Fisher’s exact test (Fisher’s exact test used if strata comprised a 
sample size  ≤ 5). To calculate multiple logistic regression models, 
univariate regressions of each factor was performed and all param-
eters fitted together in a single model. Subsequently, variables were 
removed or added back one after the other in order to improve the 
model. In the present document, only the final models including 
factors contributing to significant differences are shown. A p value 
<0.05 was considered significant, and findings were corrected for 
multiple testing using Bonferroni correction.
 Ethical Considerations 
 The SIBDCS is approved by the local ethical committees (IRB 
approval number: EK-1316, approved on February 5, 2007 by the 
Cantonal Ethics Committee of the Canton Zürich, Switzerland). 
Written informed consent was obtained before inclusion in the 
cohort.
 Results 
 Demographic Aspects and Disease Characteristics 
 In this study, we analysed a total of 1,843 IBD patients, 
consisting of 1,073 (58.2%) CD, 734 (39.8%) UC and 36 
(2.0%) IC patients. Five hundred and thirty patients 
(49.4%) being males were counted in the CD and 429 
(55.7%) in the UC/IC subgroup. Of the entire set of pa-
tients, 53 persons (2.88%) were identified having a homo-
zygous variant of the PTPN2 polymorphism (CC), 493 
(26.8%) carrying the heterozygous form (CT), and 1,297 
(70.4%) the homozygous wild-type (TT). According to a 
chi-square test, no significant difference regarding geno-
type distribution was detected between CD, UC and IC 
patients ( table  1 ). Further, no difference regarding the 
distribution of the genotypes was found between different 
ethnic groups (online suppl. table 1; for all online suppl. 
material, see www.karger.com/doi/10.1159/000444479).
 The median age of first diagnosis was at 25.6 in CD 
patients, whereas it was at 30.9 years for UC. An ileoco-
lonic disease location (L3 according to Montreal and 
Vienna Classification) was with 37.1% the most com-
monly affected site in CD, followed by colonic (L2; 
30.7%) and ileal (L1; 28.2%) disease location. Further-
more, 377 CD patients (35.1%) suffered from stenosis 
and 461 CD patients (43.0%) had a fistulising disease 
course. In UC, 42.0% of the patients featured wide-
spread involvement of the whole colon (pancolitis, E3 
according to Montreal classification); in 42.0%, the dis-
ease reached up the splenic flexure (left-sided colitis, 
E2), and only in 12.9%, UC was limited to the anorectal 
region (proctitis, E1). In 3.1%, the exact disease location 
remained undetermined.
 About one third (36.8%) of CD patients but only 1.7% 
of the UC subgroup had undergone IBD-related surgeries 
in the past. EIM were present in 44.0% of the patients with 
CD and in 33.4% in the group with UC. When consider-
ing all patient groups, peripheral arthritis and arthralgia 
were the most common EIM. Osteopenia/osteoporosis 
(18.7%), adverse effect of a treatment (10.5%) and gall-
stones (5.3%) were the most frequent complications in 
CD patients, whereas in UC patients, osteopenia/osteo-
porosis (13.1%), adverse effect of a treatment (10.4%) and 
nephrolithiasis (3.0%) were the most frequent. More de-
tailed numbers about the occurrence of EIM and other 
disease-related complications, as well as an overview 
about patients’ demographics and disease characteristics 
can be found in online supplementary table 2.
Table 1.  The distribution of the 3 genotypes among CD, UC and 
IC patients in our data set
Patients per 
genotype, %
CD UC IC Total
TT 753 (70.2) 518 (70.6) 26 (72.2) 1,297 (70.4)
CT 282 (26.3) 201 (27.4) 10 (27.8) 493 (26.8)
CC 38 (3.5) 15 (2.0) 0 53 (2.9)
Total 1,073 734 36 1,843
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 Factors Associated with CC-Genotype 
 In a first step, we assessed whether disease character-
istics differ between homozygous carriers of the PTPN2 
variant allele (CC genotype), when compared to hetero-
zygous carriers (CT genotype) and non-carriers (TT gen-
otype). In CD patients, univariate logistic regression anal-
ysis revealed that the CC genotype was associated with a 
higher age at first diagnosis (OR 1.315; 95% CI 1.068–
1.620; p  = 0.010) and the existence of gallstones (OR 
4.793; 95% CI 2.000–11.490; p < 0.001;  table 2 ).
 In the subsequent multiple regression analysis, these 
2 factors of the CC-genotype remained statistically sig-
nificant. Moreover, the disease location, in particular 
colonic disease (L2) localization, was found to be close 
to reach significance in the univariate regression model 
(p = 0.069). Colonic disease localisation was significant-
ly correlated with the CC genotype when considering 
the age at diagnosis and the presence of gallstones in 
the analysis (OR 2.620; 95% CI 1.054–6.514; p < 0.038; 
 table 3 ).
Table 2.  Univariate regression analysis of CD patients at a 5% level to identify factors associated with the CC 
genotype
Presence of CC genotype in CD patients OR (95% CI) p value
Gender
Male 1 (ref.) –
Female 0.912 (0.473–1.758) 0.783
Age at diagnosis (decades) 1.315 (1.068–1.620) 0.010
Current CD location
L1 1 (ref.) –
L2 2.296 (0.939–5.617) 0.069
L3 1.427 (0.562–3.621) 0.455
Fistula or abscess (FAF_any)
No 1 (ref.) –
Yes 1.267 (0.657–2.443) 0.480
Stenosis (sten_any)
No 1 (ref.) –
Yes 1.271 (0.651–2.482) 0.482
Intestinal surgery
No 1 (ref.) –
Yes 1.076 (0.547–2.118) 0.831
Other medical history*
Psoriasis 1.032 (0.242–4.408) 0.966
TBC Omitted since TBC predicts ‘no CC’ perfectly –
Complications*
Osteopenia/osteoporosis 0.855 (0.351–2.078) 0.729
Deep venous thrombosis Omitted since it predicts ‘no CC’ perfectly –
Pulmonary embolism Omitted since it predicts ‘no CC’ perfectly –
Gallstones 4.793 (2.000–11.49) 0.001
Nephrolithiasis 1.608 (0.372–6.963) 0.525
Malabsorption syndrome 1.855 (0.549–6.269) 0.320
Perforation/peritonitis 1.433 (0.332–6.179) 0.629
Adverse effect of a treatment 1.333 (0.508–3.495) 0.559
Extraintestinal manifestations*
Peripheral arthritis/arthralgia 0.687 (0.329–1.437) 0.319
Uveitis/iritis 2.226 (0.839–5.904) 0.108
Pyoderma gangrenosum 3.031 (0.374–24.568) 0.299
Erythema nodosum 1.661 (0.493–5.592) 0.413
Aphthous oral ulcers/stomatitis 0.296 (0.040–2.186) 0.233
Ankylosing spondylitis Omitted since it predicts ‘no CC’ perfectly –
Primary sclerosing cholangitis 5.478 (0.624–48.103) 0.125
Other Omitted since it predicts ‘no CC’ perfectly
 * For each complication or EIM, the value ‘no’ is the reference.
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 When analysing all UC/IC patients, pancolitis was the 
only factor that was significantly associated with the CC-
genotype (OR 4.581; 95% CI 1.267–16.556; p = 0.020). Of 
note, the results were similar when IC patients were not 
included in the analysis (OR 4.938; 95% CI 1.366–17.857; 
p = 0.015;  table 3 ). Further, the distribution of genotypes 
was different when comparing patients suffering from 
pancolitis with patients displaying another disease loca-
tion (p = 0.020;  table 4 ).
 Factors Associated with the Presence of the C-Allele 
 For some genes, the presence of one variant allele has an 
effect on protein function, and heterozygous carriers are 
similarly affected as homozygous carriers (dominant inher-
itance)  [18, 19] . Hence, in a next step, we assessed whether 
the presence of the C-allele (including genotypes CC and 
CT) in PTPN2 affects clinical parameters. Grouping all CD 
patients with a C-allele together revealed that uveitis was 
positively associated with the C-allele (OR 2.020; 95% CI 
1.201–3.398; p = 0.008), while aphthous oral ulcers revealed 
a negative association (OR 0.578; 95% CI 0.335–0.998; p = 
0.049). Although the p value was at the borderline to statis-
tical significance for both correlations, this remained sig-
nificant in a multiple regression model, while no addition-
al parameters were found to add significance when includ-
ed in the multiple regression analysis ( table 5 ).
 When all UC/IC patients carrying the C-allele (CC and 
CT genotype) were compared to non-carriers (TT vari-
ant), we found that the age at diagnosis was higher in pa-
tients carrying the C-allele (OR 1.122; 95% CI 1.001–1.257; 
p = 0.049;  fig. 1 ), while disease-related intestinal surgery 
(OR 3.056; 95% CI 1.011–9.239; p = 0.048) was more com-
mon in C-allele carriers. Again, the p value was margin-
ally below the significance threshold of p = 0.05, but here 
also the combination of the individually significant factors 
in a multiple logistic regression confirmed significance. 
Further, when IC patients were excluded from the analy-
sis, the difference was even more significant (p = 0.02;  ta-
ble 5 ), additionally confirming our initial finding.
 Genotype Distribution Regarding Treatment 
Characteristics 
 The distribution of genotypes (CC, CT and TT) was 
separately analysed for various treatment characteristics 
OR 95% CI p value
CD patients 
Age at diagnosis (decades) 1.306 1.055, 1.616 0.014
Presence of gallstones 4.707 1.923, 11.523 0.001
Current CD location
L1 1 (ref.)
L2 2.620 1.054, 6.514 0.038
L3 1.733 0.670, 4.483 0.257
UC patients*
Current disease location is pancolitis 4.938 1.366, 17.857 0.015
All patients
Age at diagnosis, years 1.021 1.003, 1.039 0.024
Presence of gallstones 3.831 1.656, 8.863 0.002
 * IC patients are excluded in this analysis.
Distribution of pancolitis* TT CT CC Total
Pancolitis** 209 (67.9) 88 (28.6) 11 (3.6) 308 (100)
Other location** 293 (72.7) 107 (26.6) 3 (0.7) 403 (100)
 * Only UC patients with known disease location have been included in the analysis.
** According to a Fisher’s exact test, these 2 distributions are significantly different 
(p = 0.020).
Table 3.  Multiple regression analysis to 
identify factors associated with the CC gen-
otype of CD patients, UC patients, or all 
patients together as indicated. Although all 
parameters listed in online supplementary 
table 2 have been tested, only factors con-
tributing to significance are depicted here
Table 4.  Distribution of genotypes in UC 
patients with pancolitis compared to other 
disease locations
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such as medication, response to this medication and IBD-
related intestinal surgery. In some cases, this distribution 
was significantly different from the global distribution of 
genotypes among our patient collective.
 All patients who ever received anti-TNF antibody 
therapy were analysed according to their treatment re-
sponse. Distribution of genotypes for those patients with 
response to anti-TNF therapy (7 CC/37 CT/71 TT) sig-
nificantly differed from the overall distribution (53 
CC/493 CT/1,297 TT; p value 0.05, chi-square test;  ta-
ble 6 ;  fig. 2 ). A similar result was obtained, considering 
the presence of C-allele (CT and CC genotype combined; 
p value 0.05;  table 6 ). When analysing patients stratified 
according to the specific anti-TNF antibody, similar re-
sults were obtained for patients receiving infliximab, that 
is, CC and CT carriers tended to respond more often to 
infliximab treatment than patients homozygous for the T 
allele ( table 6 ). Due to a smaller sample size, however, this 
effect did not reach statistical significance. Only 2 pa-
tients who received adalimumab responded to the treat-
ment and none of the patients who received certolizumab 
pegol responded to treatment; we therefore cannot con-
clude whether the presence of the C allele affects the re-
sponse to these 2 drugs. Of note, however, the adalim-
umab responders were both heterozygous carriers of the 
C allele ( table 6 ).
 For other parameters such as the response to treat-
ment with steroids or the use of immunomodulators, no 
significant difference was found regarding the distribu-
tion of genotypes.
 Discussion 
 In this study, we used prospectively obtained patient 
data from the SIBDCS to analyse the clinical impact of 
SNP rs1893217 in the PTPN2 gene with respect to disease 
course and treatment response. It has been suggested that 
SNP rs1893217 influences the mRNA expression and en-
zymatic activity of PTPN2  [4] . The consequences of an 
altered mRNA and protein expression as well as enzy-
matic activity of PTPN2 have been well described in many 
in vitro and in vivo experiments and a possible role for 
PTPN2 in chronic inflammatory disorders has been sug-
gested  [4, 8, 11–15] . Given the growing evidence that 
PTPN2 is crucially involved in the pathogenesis of IBD, 
it is of great interest to determine whether the presence of 
genetic polymorphisms resulting in altered PTPN2 func-
tion, might affect the clinical course of IBD. Our study 
adds important new findings to the existing body of 
knowledge about PTPN2. With the consideration and 
analysis of disease and treatment characteristics, we suc-
cessfully connected the biomedical understanding of a 
PTPN2 polymorphism with the clinical appearance of 
IBD. A further strength of this study is the large and stan-
dardized data set that was available from the prospective 
multi-centre nationwide SIBDC. This data represent a 
typical Western population and therefore enables direct 
comparison with many other studies in the field.
Table 5.  Multiple regression analysis of CD, UC/IC and UC pa-
tients for factors associated with presence of the C-allele
OR 95% CI p value
CD
EIM
Uveitis 2.020 1.201–3.398 0.008
Aphthous oral ulcers 0.578 0.335–0.998 0.049
UC/IC
Age at diagnosis (decades) 1.122 1.001–1.257 0.049
Intestinal surgery 3.056 1.011–9.239 0.048
UC (excluding IC)
Age at diagnosis, years 1.014 1.002–1.026 0.020
EIM – peripheral arthritis 1.394 0.961–2.022 0.080
Current disease location is 
pancolitis 1.382 1.001–1.928 0.049
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 Fig. 1. The CC-genotype results in increased age of first diagnosis. 
The graph depicts distribution of age at first diagnosis, stratified 
according to PTPN2 genotype in SNP rs1893217. The boxes depict 
the following information: median (middle line), 25th–75th quar-
tile (box borders), minimum–maximum (whiskers). 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
25
 - 
2/
13
/2
01
7 
2:
22
:1
3 
PM
 Spalinger   et al. Digestion 2016;93:182–192
DOI: 10.1159/000444479
188
Table 6.  Association of PTPN2 SNP rs1893217 with anti-TNF therapy
Genotype – all patients, % CC CT TT Total
Therapy with anti-TNF
No 40 (2.6) 417 (26.5) 1,114 (70.9) 1,571
Yes 13 (4.8) 76 (27.9) 83 (67.3) 272
Total 53 (2.9) 493 (26.8) 1,297 (70.4) 1,843
Anti-TNF therapy failed
No 7 (6.1) 37 (32.2) 71 (61.7) 115
Yes 5 (3.3) 39 (25.5) 109 (71.2) 153
Total 12 (4.5) 76 (28.4) 180 (67.2) 268
Existence of C-allele – all patients, % Yes No Total
Therapy with anti-TNF
No 457 (29.1) 1,114 (70.9) 1,571
Yes 89 (32.7) 183 (67.3) 272
Total 546 (29.6) 1,297 (70.4) 1,843
Anti-TNF therapy failed
No 44 (38.3) 71 (61.7) 115
Yes 44 (28.8) 109 (71.2) 153
Total 88 (32.8) 180 (67.2) 268
Genotype – CD patients, % CC CT TT Total
Therapy with anti-TNF
No 26 (3.0) 226 (25.9) 621 (71.1) 873
Yes 12 (6.0) 56 (28.0) 132 (66.0) 200
Total 38 (3.5) 282 (26.3) 753 (70.2) 1,073
Anti-TNF therapy failed
No 6 (6.6) 28 (30.8) 57 (62.6) 91
Yes 5 (4.7) 28 (26.4) 73 (68.9) 106
Total 11 (5.6) 56 (28.4) 130 (66.0) 197
Existence of C-allele – CD patients, % Yes No Total
Therapy with anti-TNF
No 252 (28.9) 621 (71.1) 873
Yes 68 (34.0) 132 (66.0) 200
Total 320 (29.8) 753 (70.2) 1,073
Anti-TNF therapy failed
No 34 (37.4) 57 (62.6) 91
Yes 33 (31.1) 73 (68.9) 106
Total 67 (34.0) 130 (66.0) 197
Genotype – UC patients*, % CC CT TT Total
Therapy with anti-TNF
No 14 (2.1) 182 (27.4) 469 (70.5) 665
Yes 1 (1.5) 19 (27.5) 49 (71.0) 69
Total 15 (2.0) 211 (27.4) 544 (70.7) 734
Anti-TNF therapy failed
No 1 (4.8) 8 (38.1) 12 (57.1) 21
Yes 0 (0.0) 11 (23.4) 36 (76.6) 47
Unknown 1 1
Total 1 (1.5) 20 (27.5) 49 (71.0) 69
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 We found that both, CD and UC/IC patients carrying 
the CC-genotype were older at the onset of disease. De-
spite this later disease onset, we found that UC/IC pa-
tients carrying the CC-genotype suffered from a more ex-
tensive disease, namely, pancolitis. As UC characteristi-
cally develops from the distal to the proximal colon, 
pancolitis indicates an aggravated and extensive disease. 
These findings are further supported by the fact that UC/
IC patients who carried a C-allele – despite later disease 
onset – were more likely to require intestinal surgery, 
mostly proctocolectomy. Pancolitis and EIM such as pe-
ripheral arthritis have been associated with active and ad-
vanced disease and might add up to an aggravated disease 
course in the presence of the C-allele  [20–22] . Addition-
ally, peripheral arthritis has been linked to pancolitis  [23, 
24] . The finding that aphthous oral ulcers was less fre-
quent in C-allele carriers does not argue against our hy-
pothesis, as current literature does not suggest an asso-
ciation between aphthous oral ulcers and disease activity 
 [20, 25] . Consequently, our results suggest that UC/IC 
patients homozygous for the C-allele are prone to a more 
rapid, severe disease course.
 In CD, we found the existence of a C-allele to be a risk 
factor for uveitis but also protective for aphthous oral ul-
cers. In analogy to the C-allele in UC/IC, currently we 
cannot fully explain these findings as both EIM have been 
reported to actually often occur together  [20] . This dis-
crepancy could at least partially be explained by the fact 
that aphthous oral ulcers are influenced by a variety of 
other factors unrelated to IBD  [26] .
 CD patients carrying the CC genotype suffered more 
often from gallstones. Formation of gallstones is a typical 
complication in CD, partially due to an impaired entero-
hepatic circulation of bile salts  [27] and a downregulated 
Existence of C-allele – UC patients*, % Yes No Total
Therapy with anti-TNF
No 205 (29.4) 493 (70.6) 698
Yes 21 (29.2) 51 (70.8) 72
Total 226 (29.4) 544 (70.7) 770
Anti-TNF therapy failed
No 10 (41.7) 14 (58.3) 24
Yes 11 (23.4) 36 (76.6) 47
Total 21 (29.6) 50 (70.4) 71
Genotype – all patients, % CC CT TT Total
Infliximab therapy failed
No 7 (6.1) 36 (31.6) 71 (62.2) 114
Yes 5 (3.9) 32 (24.8) 92 (71.3) 129
Total 12 (4.9) 68 (28.0) 163 (67.1) 243
 * Excluding IC patients.
Table 6. (continued)
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 Fig. 2. Patients carrying the C-allele respond more often to anti-
TNF treatment. The graph represents a percentage of patients car-
rying the indicated genotype in SNP rs1893217, who responded to 
anti-TNF treatment. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
25
 - 
2/
13
/2
01
7 
2:
22
:1
3 
PM
 Spalinger   et al. Digestion 2016;93:182–192
DOI: 10.1159/000444479
190
ileal bile acid uptake transporter  [28] . Severe disease with 
widespread inflammation in the ileum limits the surface 
for reabsorption of bile salts to a minimum and could 
therefore be explanatory for an increased risk for gall-
stones. All in all, the presence of the C-allele is associated 
with a more severe disease course. This manifests in ex-
tensive intestinal disease, the need for intestinal surgery, 
a higher prevalence of certain EIM and characteristic dis-
ease-related complications.
 In our study population, CD patients with this risk 
variant were more likely to respond to anti-TNF antibody 
treatment. Results from previous studies proved PTPN2 
to be a key regulator of the effects of the pro-inflammato-
ry cytokine TNF, and a negative feedback loop between 
TNF and PTPN2 is presumed  [9, 29] . It is known that 
TNF increases the expression of PTPN2 in intestinal epi-
thelial cells  [9] . In reverse, PTPN2 is an important inhib-
itor of the secretion of proinflammatory cytokines like 
TNF. This has been confirmed by detecting significantly 
higher TNF levels in PTPN2-deficient mice  [30, 31] . We 
have previously shown that the presence of the PTPN2 
SNP rs1893217 causes a diminished function of PTPN2 
protein  [4] . In that way, the inhibitory signals for TNF in 
the negative feedback loop are weakened and conse-
quently more TNF is released. TNF reaches higher serum 
levels in patients with autoimmune diseases and is an es-
sential pro-inflammatory cytokine that maintains chron-
ic inflammation  [31–33] . By blocking the excessive TNF 
production with anti-TNF agents, this viscous inflamma-
tion-maintaining cycle can be interrupted. This could ex-
plain our observed higher response rate to anti-TNF in 
patients with a C-allele compared to those without.
 Our results are of interest for pharmacotherapy of 
IBD, as they might prove the legitimation for early use of 
anti-TNF antibodies in certain patient subgroups, and 
might help identify patients that are more susceptible to 
anti-TNF treatment. To date, in daily practice, anti-TNF 
antibodies are mainly used in IBD patients not respond-
ing to or being intolerant to steroids and immunomodu-
lators, also known as the ‘step-up’ approach  [34, 35] . Un-
fortunately, a decade of experience with anti-TNF anti-
bodies indicates that about one third of IBD patients are 
anti-TNF antibody non-responders  [36–40] . Although 
many factors such as young age at diagnosis, non-smok-
ing (OR 2.33  [41] ), pANCA negativity (OR 1.87  [42] ), 
and various gene expression profiles (PTPN2 polymor-
phisms not included) have been associated with a higher 
response rate, so far none of them has been clearly imple-
mented in clinical decision making  [39, 41–44] . As the 
use of anti-TNF antibodies is constantly increasing, the 
elaboration of a model for prediction of response is of a 
major interest. Considering our results and the current 
available literature, a multifactorial model that includes 
PTPN2 polymorphisms might be the most promising 
predictive approach to achieve this. Nevertheless, our 
data might suggest the early use of anti-TNF antibodies 
in UC patients carrying the disease-associated PTPN2 
variant. However, since patient numbers of CD patients 
with the CC genotype treated with anti-TNF antibodies 
were low, and our entire data were obtained only from a 
single cohort, validation of our findings in an indepen-
dent patient cohort or in a prospective trial would clearly 
be necessary before drawing a final conclusion on the ef-
fect of the C-allele regarding anti-TNF medication.
 After all, there are some methodological limitations in 
this study. UC patients with a particularly severe course of 
disease might be over-represented in our UC patient col-
lective, since in general, more patients with a severe disease 
course are included in the SIBDCS and a significant num-
ber of patients with a mild disease course might not be 
represented in this cohort. Furthermore, we face a selec-
tion bias that applies to most cohort studies: difficult cases 
tend to converge in specialized IBD clinics, while mild cas-
es are commonly treated at private practice gastroenter-
ologists. Although our cohort features a fraction of IBD 
patients receiving care in gastroenterology private practice 
(about 30% of patients), those IBD patients treated in sec-
ondary or tertiary referral centres are somewhat overrep-
resented in our cohort. Additionally, the awareness of 
studies is naturally higher at the institution where they are 
conducted. It is thus likely that blood samples for genotyp-
ing were obtained more frequently at our clinic than in 
district hospitals or gastroenterology private practices. 
Further, our data were generated exclusively in the SIBDC. 
Although the SIBDC is very well characterized and repre-
sents a typical European cohort  [16] , validation of our 
finding in additional, independent cohorts will be neces-
sary to confirm our findings. Nevertheless, since only few 
data exist that describe a clinical relevance of IBD candi-
date genes, our findings might critically contribute to a 
better understanding of the complex interaction between 
genetic predispositions and the clinical appearance of IBD.
 In summary, this is the first study that showed that 
IBD patients homozygous or heterozygous for the PTPN2 
SNP rs1893217 were at greater risk for developing a se-
vere course of disease but were more likely to respond to 
treatment with anti-TNF antibodies. However, to draw a 
definite conclusion regarding treatment recommenda-
tions for patients with PTPN2 polymorphisms, our re-
sults need to be confirmed by further clinical studies.
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